Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Endocrinology

Looking Ahead: Puberty and Adulthood with Laron Syndrome

At a Glance

Laron syndrome may delay and prolong puberty and can affect body fat, fertility, blood sugar, cholesterol, and liver health in adulthood. Mecasermin usually stops when growth plates close, but ongoing endocrine care and routine cancer screening remain important.

As your child grows, the focus of care will naturally shift from promoting height to maintaining long-term metabolic health. Understanding what to expect during puberty and adulthood can help you prepare for these transitions and advocate for your child’s lifelong well-being.

Puberty: A Slower, Later Timeline

In children with Laron syndrome, puberty often follows a different timeline than in their peers. It is common for the onset of puberty to be delayed [1][2].

  • Delayed and Prolonged: Research has shown that puberty may start later and take longer to complete [1]. For example, in a review of untreated males, about 35% experienced delayed puberty, and for the vast majority (77%), the process was prolonged [1].
  • Sexual Development: While development may be slower, sexual maturation does occur. However, fertility varies among individuals [2]. Reproductive health can be influenced by genotype, metabolic factors like obesity, and specific anatomical developments [3]. If you have concerns about delayed puberty or future fertility, an endocrinologist or reproductive specialist can provide tailored support.
  • Physical Findings: In males, features such as a micropenis (a smaller than average penis) are common [1]. Your endocrinologist will monitor these developments and may discuss hormone support if needed.

Metabolic Health in Adulthood

Laron syndrome affects how the body processes energy, leading to a unique metabolic profile in adulthood.

  • Body Composition: Most adults with Laron syndrome have a high percentage of body fat, even if their BMI (Body Mass Index) doesn’t seem extremely high [4][5]. This is often called truncal obesity [1].
  • Contrasting Health Profiles: Interestingly, different groups of patients show different health outcomes.
    • In some groups (such as an Israeli cohort), adults frequently developed metabolic syndrome, including high blood pressure, high cholesterol (dyslipidemia), and type 2 diabetes [4].
    • In contrast, a famous cohort in Ecuador showed a lower risk of diabetes and higher insulin sensitivity (the body’s ability to use sugar effectively) despite having high body fat [5][6].
  • Cardiovascular Care: Because the risk of high cholesterol and fatty liver disease is real, adult care involves individualized, regular monitoring of heart health and blood sugar levels [4][7].

The Question of “Cancer Protection”

You may hear that people with Laron syndrome are “protected” from cancer. This idea comes from long-term observational studies of the Ecuadorian group, which found significantly lower rates of cancer compared to their relatives [8][6].

  • The Theory: Scientists believe that because these individuals have very low levels of IGF-1—a hormone that helps cells grow and divide—this may influence cell replication [8][9].
  • The Reality: This finding is not absolute and should be viewed as an observational association, not a proven protection. There have been documented cases of cancer in people with Laron syndrome [10]. It is vital to continue routine cancer screenings according to age, sex, and family history guidelines, as the findings from one cohort may not apply to everyone [10][11].

When Treatment Ends

The specialized treatment with Mecasermin (IGF-1) is specifically designed to promote height.

  • Closing Growth Plates: Growth-promoting treatment typically stops when the growth plates (epiphyses) in the long bones close [12]. This closure is triggered by the hormones of puberty [13].
  • Bone Age Monitoring: Your doctor will use hand X-rays to determine “bone age.” Once the bones have finished maturing and the plates have fused, no further height can be gained, and the injections are usually discontinued [14][12].

While the injections stop, the need for a “home” for your child’s care—ideally with an adult endocrinologist familiar with rare growth disorders—continues into adulthood [15]. Moving from pediatric to adult care is a significant milestone that ensures your child’s metabolic and reproductive health stays monitored throughout their life.

Common questions in this guide

Is delayed puberty common in children with Laron syndrome?
Puberty often begins later in children with Laron syndrome and may take longer to complete. Sexual maturation generally occurs, but timing varies, so an endocrinologist can monitor development and discuss evaluation or support when needed.
Can Laron syndrome affect fertility?
Fertility varies among people with Laron syndrome. Genetic factors, body composition and metabolic health, and reproductive anatomy can all influence reproductive health, so an endocrinologist or reproductive specialist can provide individualized assessment and support.
What health problems should adults with Laron syndrome be monitored for?
Adult care may include regular checks of blood pressure, cholesterol, blood sugar, and liver health because metabolic syndrome, abnormal cholesterol, diabetes, and fatty liver disease can occur. Monitoring should be individualized because health risks differ among people and patient groups.
Does Laron syndrome protect against cancer?
Some observational research found lower cancer rates in a specific Ecuadorian group, but this does not prove complete protection, and cancer has occurred in people with Laron syndrome. Routine cancer screening based on age, sex, and family history remains important.
When is mecasermin stopped in Laron syndrome?
Mecasermin is usually discontinued when the growth plates close and the bones have finished maturing, because additional height cannot be gained after the plates fuse. Doctors use growth tracking and hand X-rays to assess bone age and remaining growth potential.
Does care continue after a child reaches adult height?
Yes. Even after height-focused injections stop, ongoing adult endocrinology care can monitor metabolic, reproductive, and general health. A planned transition from pediatric to adult care helps prevent gaps in lifelong follow-up.

Get notified when new evidence is published on Laron syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Role of the GH-IGF1 axis on the hypothalamus-pituitary-testicular axis function: lessons from Laron syndrome.

    Cannarella R, Crafa A, La Vignera S, et al.

    Endocrine connections 2021; (10(9)):1006-1017.

    PMID: 34319907
  2. 2

    LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME.

    Laron Z

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2015; (21(12)):1395-402 doi:10.4158/EP15939.RA.

    PMID: 26401581
  3. 3

    Treatment for Infertility in Laron Syndrome: A Case Report.

    Alhazidou E, Vlachadis N, Androulaki M, et al.

    Cureus 2022; (14(12)):e33090 doi:10.7759/cureus.33090.

    PMID: 36721555
  4. 4

    Adult patients with Laron syndrome tend to develop the metabolic syndrome.

    Laron Z, Kauli R, Silbergeld A

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2024; (78()):101605 doi:10.1016/j.ghir.2024.101605.

    PMID: 39084176
  5. 5

    GH Receptor Deficiency in Ecuadorian Adults Is Associated With Obesity and Enhanced Insulin Sensitivity.

    Guevara-Aguirre J, Rosenbloom AL, Balasubramanian P, et al.

    The Journal of clinical endocrinology and metabolism 2015; (100(7)):2589-96 doi:10.1210/jc.2015-1678.

    PMID: 25985182
  6. 6

    Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.

    Guevara-Aguirre J, Bautista C, Torres C, et al.

    Reviews in endocrine & metabolic disorders 2021; (22(1)):59-70 doi:10.1007/s11154-020-09602-4.

    PMID: 33047268
  7. 7

    Normal or improved cardiovascular risk factors in IGF-I-deficient adults with growth hormone receptor deficiency.

    Guevara-Aguirre J, Mishra A, Canepa M, et al.

    Med (New York, N.Y.) 2024; (5(7)):816-825.e4 doi:10.1016/j.medj.2024.03.022.

    PMID: 38677286
  8. 8

    Cancer in Ecuadorian subjects with Laron syndrome (ELS).

    Guevara-Aguirre J, Peña G, Pazmiño G, et al.

    Endocrine-related cancer 2023; (30(6)).

    PMID: 36971780
  9. 9

    Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.

    Werner H, Sarfstein R, Nagaraj K, Laron Z

    Cells 2020; (9(11)) doi:10.3390/cells9112446.

    PMID: 33182502
  10. 10

    Marjolin's Ulcer in Laron Syndrome - an Unexpected Combination: A Case Report.

    de la Paz EM

    Malaysian orthopaedic journal 2020; (14(1)):78-80 doi:10.5704/MOJ.2003.012.

    PMID: 32296486
  11. 11

    Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.

    Janecka A, Kołodziej-Rzepa M, Biesaga B

    In vivo (Athens, Greece) 2016; (30(4)):375-81.

    PMID: 27381597
  12. 12

    Short and tall stature: a new paradigm emerges.

    Baron J, Sävendahl L, De Luca F, et al.

    Nature reviews. Endocrinology 2015; (11(12)):735-46 doi:10.1038/nrendo.2015.165.

    PMID: 26437621
  13. 13

    Approach to the Peripubertal Patient With Short Stature.

    Torres-Santiago L, Mauras N

    The Journal of clinical endocrinology and metabolism 2024; (109(7)):e1522-e1533 doi:10.1210/clinem/dgae011.

    PMID: 38181434
  14. 14

    Sequential measurements of IGF-I serum concentrations in adolescents with Laron syndrome treated with recombinant human IGF-I (rhIGF-I).

    Breil T, Kneppo C, Bettendorf M, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(8)):895-902 doi:10.1515/jpem-2018-0139.

    PMID: 29995632
  15. 15

    Growth hormone insensitivity: Mexican case report.

    Castilla-Cortazar I, De Ita JR, Aguirre GA, et al.

    Endocrinology, diabetes & metabolism case reports 2017; (2017()) doi:10.1530/EDM-17-0126.

    PMID: 29147569

This page provides general information about puberty and adulthood with Laron syndrome for informational purposes only and does not constitute medical advice. Your child’s endocrinology team should tailor growth, hormone, metabolic, reproductive, and screening decisions to their specific situation.